Literature DB >> 1685995

Differences in functional cyclic AMP compartments mediating lipolysis by isoprenaline and BRL 37344 in four adipocyte types.

C Hollenga1, F Brouwer, J Zaagsma.   

Abstract

Triglyceride mobilization and adenylyl cyclase activation in adipocytes from Wistar rats, lean Zucker (Fa/?) rats, obese Zucker (fa/fa) rats and humans were investigated in concentration-response studies with (-)-isoprenaline and the atypical beta 3-adrenoceptor selective agonist BRL 37344. Maximum FFA production by both agonists was identical in Wistar rat and lean Zucker rat adipocytes, while obese Zucker rat adipocytes and human adipocytes produced significantly less FFA, especially with BRL 37344. Maximum adenylyl cyclase activation by (-)-isoprenaline was similar for all types of adipocyte ghosts, whereas BRL 37344 was a partial agonist in all cases with the lowest intrinsic activity in human adipocytes. For (-)-isoprenaline the relationship between cAMP and lipolysis was steepest with Wistar rat adipocytes, followed by human and lean Zucker rat adipocytes, while obese Zucker rat cells showed a shallow relationship. For BRL 37344, the relationship was very steep and similar for all four adipocyte types, despite the marked differences in maximal lipolysis and cyclic AMP production. The results strongly argue in favour of cyclic AMP compartmentalization, the activity ratio between the functional and the non-functional compartment being least favourable in obese Zucker rat adipocytes. The atypical beta 3-adrenoceptor agonist BRL 37344 very efficiently directs the generated cyclic AMP into the functional compartment in all four adipocytes types investigated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685995     DOI: 10.1016/0014-2999(91)90590-m

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Autonomic regulation of T-lymphocytes: Implications in cardiovascular disease.

Authors:  Safwan K Elkhatib; Adam J Case
Journal:  Pharmacol Res       Date:  2019-06-06       Impact factor: 7.658

Review 2.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

3.  Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle.

Authors:  Y L Liu; M A Cawthorne; M J Stock
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Multiple lipolysis defects in the insulin resistance (metabolic) syndrome.

Authors:  S Reynisdottir; K Ellerfeldt; H Wahrenberg; H Lithell; P Arner
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

5.  Classical and atypical binding sites for beta-adrenoceptor ligands and activation of adenylyl cyclase in bovine skeletal muscle and adipose tissue membranes.

Authors:  M N Sillence; M L Matthews
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

6.  Demonstration of an in vivo functional beta 3-adrenoceptor in man.

Authors:  S Enocksson; M Shimizu; F Lönnqvist; J Nordenström; P Arner
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

7.  Catecholamine resistance in fat cells of women with upper-body obesity due to decreased expression of beta 2-adrenoceptors.

Authors:  S Reynisdottir; H Wahrenberg; K Carlström; S Rössner; P Arner
Journal:  Diabetologia       Date:  1994-04       Impact factor: 10.122

8.  Evidence for a functional beta 3-adrenoceptor in man.

Authors:  F Lönnqvist; S Krief; A D Strosberg; S Nyberg; L J Emorine; P Arner
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.